Erin Burkhart - Mar 15, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
GVP, Chief Accounting Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Mar 15, 2024
Transactions value $
-$31,200
Form type
4
Date filed
3/19/2024, 08:55 PM
Previous filing
May 18, 2023
Next filing
Apr 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock +Grant/Award $0 +4,720 +33.49% $0.00 18,814 Mar 15, 2024 Direct F1
transaction BMRN Common Stock -Tax liability -$31,200 -372 -1.98% $83.87 18,442 Mar 18, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) +Grant/Award $0 +7,050 $0.00 7,050 Mar 15, 2024 Common Stock 7,050 $83.87 Direct F2

Explanation of Responses:

Id Content
F1 Restricted stock units granted March 15, 2024. Price not applicable.
F2 Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter.